About Oncobiologics (NASDAQ:ONS)
Oncobiologics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing, manufacturing and commercializing biosimilar therapeutics. It is focused on monoclonal antibodies (mAbs) in the disease areas of immunology and oncology. The Company offers BioSymphony Platform. The Company has identified approximately eight biosimilar product candidates, of which two product candidates are ONS-3010 and ONS-1045. ONS-3010 is an adalimumab (Humira) biosimilar. The Company has initiated Phase III preparatory activities for ONS-3010. Its second product candidate, ONS-1045, is a bevacizumab (Avastin) biosimilar. The Company's other preclinical product candidate, ONS-1050, a trastuzumab (Herceptin) biosimilar, interferes with the human epidermal growth factor receptor 2 (HER2). ONS-4010 is a biosimilar to denosumab (Prolia/Xgeva), which is a human mAb. Its other biosimilar product, ONS-1055, is a biosimilar to cetuximab (Erbitux).
Industry, Sector and Symbol:
- Industry: Biotechnology & Medical Research
- Sub-Industry: N/A
- Sector: Medical
- Symbol: NASDAQ:ONS
- Previous Symbol: NYSE:ONS
- CUSIP: N/A
- Web: www.oncobiologics.com
- Debt-to-Equity Ratio: -0.01%
- Current Ratio: 0.03%
- Quick Ratio: 0.03%
Sales & Book Value:
- Annual Sales: $2.98 million
- Price / Sales: 11.76
- Book Value: ($0.23) per share
- Price / Book: -6.17
- Net Income: $-53,320,000.00
- Net Margins: -3,056.85%
- Return on Assets: -239.07%
- Employees: 83
- Outstanding Shares: 24,680,000
Frequently Asked Questions for Oncobiologics (NASDAQ:ONS)
What is Oncobiologics' stock symbol?
Oncobiologics trades on the NASDAQ under the ticker symbol "ONS."
Where is Oncobiologics' stock going? Where will Oncobiologics' stock price be in 2017?
2 brokerages have issued twelve-month price objectives for Oncobiologics' stock. Their forecasts range from $3.00 to $15.00. On average, they anticipate Oncobiologics' share price to reach $9.00 in the next year. View Analyst Ratings for Oncobiologics.
Who are some of Oncobiologics' key competitors?
Some companies that are related to Oncobiologics include Abzena PLC (ABZA), Vernalis plc (VER), OncoSec Medical Incorporated (ONCS), Senomyx (SNMX), CytRx Corporation (CYTR), OvaScience (OVAS), Aptose Biosciences (APTO), Prima BioMed Ltd (PBMD), Ohr Pharmaceuticals (OHRP), Bio-Path Holdings (BPTH), AEterna Zentaris (AEZS), Scancell Holdings Plc (SCLP), Caladrius Biosciences (CLBS), Genocea Biosciences (GNCA), Prana Biotechnology Ltd (PRAN), Cleveland BioLabs (CBLI), Can Fite Biopharma Ltd (CANF) and Fibrocell Science (FCSC).
Who are Oncobiologics' key executives?
Oncobiologics' management team includes the folowing people:
- Pankaj Mohan Ph.D., Chairman of the Board, President, Chief Executive Officer (Age 53)
- Lawrence A. Kenyon, Chief Financial Officer, Corporate Secretary (Age 52)
- Scott A. Gangloff, Senior Vice President - Development and Manufacturing (Age 43)
- Stephen J. McAndrew Ph.D., Senior Vice President - Business Strategy & Development (Age 63)
- Kogan Bao Ph.D., Vice President - Analytical Sciences (Age 47)
- Elizabeth A. Yamashita, Vice President - Regulatory Affairs (Age 56)
- Kenneth M. Bahrt M.D., Chief Medical Officer (Age 64)
- Claudio Albrecht, Director
- Yezan Haddadin, Director
- Scott A. Canute, Independent Director (Age 57)
When did Oncobiologics IPO?
(ONS) raised $35 million in an initial public offering (IPO) on Friday, May 13th 2016. The company issued 5,800,000 shares at a price of $6.00 per share. Jefferies and Barclays served as the underwriters for the IPO and Cantor Fitzgerald & Co. was co-manager.
Who owns Oncobiologics stock?
How do I buy Oncobiologics stock?
Shares of Oncobiologics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Oncobiologics' stock price today?
One share of Oncobiologics stock can currently be purchased for approximately $1.42.
How big of a company is Oncobiologics?
Oncobiologics has a market capitalization of $33.81 million and generates $2.98 million in revenue each year. Oncobiologics employs 83 workers across the globe.
How can I contact Oncobiologics?
Oncobiologics' mailing address is 7 CLARKE DRIVE, CRANBURY NJ, 08512. The company can be reached via phone at 609-619-3990 or via email at [email protected]
MarketBeat Community Rating for Oncobiologics (NASDAQ ONS)MarketBeat's community ratings are surveys of what our community members think about Oncobiologics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Analysts' Consensus Rating for Oncobiologics (NASDAQ:ONS) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||0 Sell Ratings, 1 Hold Rating, 1 Buy Rating, 0 Strong Buy Ratings|
|Consensus Rating:||Buy (Score: 2.50)|
|Consensus Price Target: ||$9.00 (533.80% upside)|
Consensus Price Target History for Oncobiologics (NASDAQ:ONS)
Analysts' Ratings History for Oncobiologics (NASDAQ:ONS)
(Data available from 11/21/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|4/13/2017||Cantor Fitzgerald||Reiterated Rating||Buy||$15.00||Low|
|4/12/2017||Jefferies Group LLC||Reiterated Rating||Hold||$3.00||High|
|6/7/2016||Barclays PLC||Reiterated Rating||Overweight||$11.00||N/A|
Earnings History for Oncobiologics (NASDAQ:ONS)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for Oncobiologics (NASDAQ:ONS)
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Oncobiologics (NASDAQ:ONS)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Oncobiologics (NASDAQ ONS)
Insider Ownership Percentage: 33.50%
Institutional Ownership Percentage: 23.37%
Insider Trades by Quarter for Oncobiologics (NASDAQ ONS)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|11/11/2016||Scott A. Gangloff||SVP||Sell||37,369||$3.75||$140,133.75|| |
Latest Headlines for Oncobiologics (NASDAQ ONS)
Oncobiologics (NASDAQ ONS) Chart for Tuesday, November, 21, 2017